Pharmaceutical Technology on MSN
Boehringer’s Jascayd gains China’s NMPA approval for PPF
China’s National Medical Products Administration (NMPA) has granted approval for Boehringer Ingelheim’s Jascayd ...
Ingelheim: Boehringer Ingelheim has announced that China's National Medical Products Administration (NMPA) has approved ...
Nerandomilast is an oral, preferential PDE4B inhibitor approved in China for the treatment of adult patients with IPF and PPF. It was also approved by the U.S. Food and Drug Administration (FDA) for ...
Major advancements in pulmonary fibrosis treatment and critical warnings regarding both indoor air quality and scientific ...
The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five years.PPF is a ...
Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and pirfenidone. The FIBRONEER trials support nerandomilast's efficacy in reducing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback